Molecular Biomarkers in Gastro-esophageal Cancer: Recent Developments, Current Trends and Future Directions

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2018 Jul 17

PMID 30008616

Citations 31

Authors

Francesca Battaglin

Madiha Naseem

Alberto Puccini

Heinz-Josef Lenz

Affiliations

Soon will be listed here.

Abstract

Gastro-esophageal adenocarcinomas (GEA) represent a severe global health burden and despite improvements in the multimodality treatment of these malignancies the prognosis of patients remains poor. HER2 overexpression/amplification has been the first predictive biomarker approved in clinical practice to guide patient selection for targeted treatment with trastuzumab in advanced gastric and gastro-esophageal junction cancers. More recently, immunotherapy has been approved for the treatment of GEA and PD-L1 expression is now a biomarker required for the administration of pembrolizumab in these diseases. Significant progress has been made in recent years in dissecting the genomic makeup of GEA in order to identify distinct molecular subtypes linked to distinct patterns of molecular alterations. GEA have been found to be highly heterogeneous malignances, representing a challenge for biomarkers discovery and targeted treatment development. The current review focuses on an overview of established and novel promising biomarkers in GEA, covering recent molecular classifications from TCGA and ACRG. Main elements of molecular heterogeneity are discussed, as well as emerging mechanisms of primary and secondary resistance to HER2 targeted treatment and recent biomarker-driven trials. Future perspectives on the role of epigenetics, miRNA/lncRNA and liquid biopsy, and patient-derived xenograft models as a new platform for molecular-targeted drug discovery in GEA are presented. Our knowledge on the genomic landscape of GEA continues to evolve, uncovering the high heterogeneity and deep complexity of these tumors. The availability of new technologies and the identification of promising novel biomarker will be critical to optimize targeted treatment development in a setting where therapeutic options are currently lacking. Nevertheless, clinical validation of novel biomarkers and treatment strategies still represents an issue.

Citing Articles

Multivariate Cox regression analysis of prognostic genes and therapeutic mechanisms of gastric cancer.

Xiao Y, Zhong Z, Yang C, Lin Z Discov Oncol. 2025; 16(1):136.

PMID: 39921793 PMC: 11807035. DOI: 10.1007/s12672-025-01907-7.

Aging and cancer: Clinical role of tumor markers in the geriatric population (Review).

Sundaresan S, Rajapriya P, Lavanya S Med Int (Lond). 2024; 4(3):21.

PMID: 39640494 PMC: 11618985. DOI: 10.3892/mi.2024.145.

A Long-term Survival Risk Prediction Model for Patients with Superficial Esophageal Squamous Cell Carcinoma.

Yang R, Wei M, Yu X, Su W, Zhou X, Chen H J Cancer. 2024; 15(19):6204-6212.

PMID: 39513114 PMC: 11540495. DOI: 10.7150/jca.99042.

Expression of Interleukin-8, Interleukin-12 and Interleukin-13 in Esophageal Squamous Cell Carcinoma: Biomarker Potentiality and Prognostic Significance.

Talukdar J, Malik A, Kataki K, Choudhury B, Baruah M, Bhattacharyya M J Gastrointest Cancer. 2024; 55(3):1239-1255.

PMID: 38910194 DOI: 10.1007/s12029-024-01063-1.

Genetic Impact of HOTAIR, LINC00951, POLR2E and HULC Polymorphisms in Histopathological and Laboratory Prognostic Factors in Esophageal Cancer in the West: A Case-Control Study.

Baili E, Gazouli M, Lazaris A, Kanavidis P, Boura M, Michalinos A Cancers (Basel). 2024; 16(3).

PMID: 38339289 PMC: 10854877. DOI: 10.3390/cancers16030537.

References

Hao N, He Y, Li X, Wang K, Wang R . The role of miRNA and lncRNA in gastric cancer. Oncotarget. 2017; 8(46):81572-81582. PMC: 5655310. DOI: 10.18632/oncotarget.19197. View

Genitsch V, Novotny A, Seiler C, Kroll D, Walch A, Langer R . Epstein-barr virus in gastro-esophageal adenocarcinomas - single center experiences in the context of current literature. Front Oncol. 2015; 5:73. PMC: 4374449. DOI: 10.3389/fonc.2015.00073. View

Vranic S . Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances. Bosn J Basic Med Sci. 2017; 17(3):274-275. PMC: 5581978. DOI: 10.17305/bjbms.2017.2366. View

Boger C, Kruger S, Behrens H, Bock S, Haag J, Kalthoff H . Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations. Ann Oncol. 2017; 28(5):1005-1014. PMC: 5406766. DOI: 10.1093/annonc/mdx047. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

Ralph C, Elkord E, Burt D, ODwyer J, Austin E, Stern P . Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010; 16(5):1662-72. DOI: 10.1158/1078-0432.CCR-09-2870. View

Mathiak M, Warneke V, Behrens H, Haag J, Boger C, Kruger S . Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization. Appl Immunohistochem Mol Morphol. 2015; 25(1):12-24. PMC: 5147042. DOI: 10.1097/PAI.0000000000000264. View

Thuss-Patience P, Shah M, Ohtsu A, Van Cutsem E, Ajani J, Castro H . Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017; 18(5):640-653. DOI: 10.1016/S1470-2045(17)30111-0. View

10.

Chang M, Uozaki H, Chong J, Ushiku T, Sakuma K, Ishikawa S . CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res. 2006; 12(10):2995-3002. DOI: 10.1158/1078-0432.CCR-05-1601. View

11.

Dulak A, Stojanov P, Peng S, Lawrence M, Fox C, Stewart C . Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013; 45(5):478-86. PMC: 3678719. DOI: 10.1038/ng.2591. View

12.

Kwak E, Ahronian L, Siravegna G, Mussolin B, Borger D, Godfrey J . Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov. 2015; 5(12):1271-81. PMC: 4670804. DOI: 10.1158/2159-8290.CD-15-0748. View

13.

Hur C, Miller M, Kong C, Dowling E, Nattinger K, Dunn M . Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013; 119(6):1149-58. PMC: 3744155. DOI: 10.1002/cncr.27834. View

14.

Park J, Yoo H, Jang W, Shin S, Kim M, Kim Y . Distribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer. Medicine (Baltimore). 2017; 96(25):e7224. PMC: 5484224. DOI: 10.1097/MD.0000000000007224. View

15.

Shirmohammadi K, Sohrabi S, Jafarzadeh Samani Z, Effatpanah H, Yadegarazari R, Saidijam M . Evaluation of altered expression of and as an early diagnostic approach in gastric cancer. J Gastrointest Oncol. 2018; 9(1):46-51. PMC: 5848032. DOI: 10.21037/jgo.2017.11.04. View

16.

Qiu Z, Sun W, Zhou C, Zhang J . HER2 expression variability between primary gastric cancers and corresponding lymph node metastases. Hepatogastroenterology. 2015; 62(137):231-3. View

17.

Zhou X, Zheng Y . Cell type-specific signaling function of RhoA GTPase: lessons from mouse gene targeting. J Biol Chem. 2013; 288(51):36179-88. PMC: 3868732. DOI: 10.1074/jbc.R113.515486. View

18.

Velho S, Fernandes M, Leite M, Figueiredo C, Seruca R . Causes and consequences of microsatellite instability in gastric carcinogenesis. World J Gastroenterol. 2014; 20(44):16433-42. PMC: 4248186. DOI: 10.3748/wjg.v20.i44.16433. View

19.

Joshi S, Maron S, Catenacci D . Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncol. 2017; 14(5):417-430. PMC: 5827797. DOI: 10.2217/fon-2017-0436. View

20.

Tan C, Qian X, Guan Z, Yang B, Ge Y, Wang F . Potential biomarkers for esophageal cancer. Springerplus. 2016; 5:467. PMC: 4833762. DOI: 10.1186/s40064-016-2119-3. View